#Sweden #Stockholm #SciBase Holding #Nomination Committee #AGMs

SciBase Holding Appoints Members for 2026 Nomination Committee

On October 22, 2025, SciBase Holding AB, a prominent player in medical technology, revealed the members of its nomination committee ahead of the upcoming Annual General Meeting (AGM) slated for May 19, 2026. This appointment comes as part of the company's ongoing commitment to shareholder engagement and effective management practices.

The newly appointed members of the nomination committee include:

• - Anders Bladh from Ribbskottet AB,
• - Derek Maetzold from Castle Biosciences Inc,
• - Maria Anderkvist from Coeli Wealth Management, and
• - Jesper Høiland, who serves as the Chairman of the Board.

These individuals have been selected in accordance with the established guidelines regarding the principles for the nomination committee, which were originally set out during the AGM held on June 17, 2025.

Importance of the Nomination Committee

A nomination committee plays a crucial role in the governance of a company. It is responsible for proposing candidates for the Board of Directors and ensuring that the company adheres to best practices in director nominations. The involvement of various stakeholders in the committee is indicative of a diverse and inclusive approach to leadership.

Jesper Høiland, the Chairman, expressed his views on the appointments, noting the wealth of experience and different perspectives that the committee members bring. This diversity is expected to enrich discussions and enhance decision-making processes leading up to the AGM.

Annual General Meeting Details

The AGM of SciBase Holding AB will take place in Stockholm. Shareholders interested in proposing items for discussion at the AGM must do so in writing. Proposals can be submitted to SciBase Holding AB (publ), addressed to the Chairman of the Board, either by mail at Box 3337, 103 67 Stockholm, or via email at the company’s dedicated email address.

Proposals must be communicated to the Board no later than seven weeks before the AGM to ensure they can be included in the official notice.

Overview of SciBase Holding

SciBase is a pioneering company in the field of medical technology, particularly focusing on dermatology. The company is best known for its innovative product, Nevisense, which employs artificial intelligence and advanced electrical impedance spectroscopy (EIS) technology to enhance diagnostic accuracy. SciBase aims to improve patient care by enabling early detection and proactive management of skin health concerns.

Founded on over 20 years of research at the Karolinska Institute in Stockholm, SciBase strives to minimize patient suffering through effective healthcare solutions and significantly contribute to reducing healthcare costs. As of June 2, 2015, the company has been trading on the Nasdaq First North Growth Market.

For further information, stakeholders are encouraged to contact:

• - Jesper Høiland, Chairman of the board at +45 612 207 30
• - Michael Colérus, CFO at +46 70 341 34 72

SciBase continues to showcase its commitment to advancing dermatological practices and ensuring that patients receive the best possible care backed by robust technology and research.